How Does Ozempic Make You Lose Weight? The Four Mechanisms Working Together

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) activates GLP-1 receptors in the brain's appetite centers, reducing hunger signals by 30-40% compared to baseline
• The medication slows gastric emptying from 90 minutes to 3-4 hours, creating mechanical fullness that persists between meals
• Semaglutide improves insulin sensitivity and reduces glucagon secretion, shifting metabolism away from fat storage
• Weight loss averages 15-17% of body weight over 68 weeks in clinical trials, with 86% of the effect coming from reduced caloric intake rather than metabolic changes

Direct answer (40-60 words)

Ozempic makes you lose weight through four simultaneous mechanisms: it activates GLP-1 receptors in the hypothalamus to suppress appetite, slows stomach emptying to create prolonged fullness, improves insulin response to reduce fat storage, and decreases food reward signaling in the brain. The combined effect reduces daily caloric intake by 500-800 calories without conscious restriction.

Table of contents

1. The 30-second answer
2. What GLP-1 actually is and why your body already makes it
3. Mechanism 1: The brain appetite pathway (the dominant effect)
4. Mechanism 2: Delayed gastric emptying (the fullness signal)
5. Mechanism 3: Insulin and glucagon rebalancing
6. Mechanism 4: Reduced food reward and craving suppression
7. What most articles get wrong about the mechanism
8. The dose-response relationship: how much semaglutide produces how much weight loss
9. Why some people lose 25% and others lose 5%: the responder question
10. The FormBlends 4-Phase Weight Loss Pattern on compounded semaglutide
11. When you should NOT expect Ozempic to work for weight loss
12. The timeline: what happens week by week
13. FAQ
14. Sources

What GLP-1 actually is and why your body already makes it

GLP-1 (glucagon-like peptide-1) is a hormone your intestines produce naturally every time you eat. The L-cells in your small intestine release it within 10 to 15 minutes of food entering your digestive tract. Its original evolutionary purpose is metabolic regulation: telling your pancreas to release insulin, telling your stomach to slow down, and telling your brain you've had enough.

The problem is that natural GLP-1 has a half-life of about 2 minutes. An enzyme called DPP-4 breaks it down almost immediately. You get a brief spike after each meal, then it's gone.

Ozempic's active ingredient, semaglutide, is a modified version of human GLP-1 with two critical changes:

1. A chemical modification that prevents DPP-4 from breaking it down
2. An albumin-binding side chain that keeps it circulating in the bloodstream

The result is a half-life of 7 days instead of 2 minutes. One weekly injection maintains constant GLP-1 receptor activation 24 hours a day, 7 days a week. This sustained activation is what produces weight loss. Your body never evolved to handle continuous GLP-1 signaling at therapeutic levels, which is why the effect is so pronounced.

The four mechanisms below all stem from activating the same GLP-1 receptors in different tissues. The weight loss is not one mechanism but the sum of all four working simultaneously.

Mechanism 1: The brain appetite pathway (the dominant effect)

The hypothalamus, specifically the arcuate nucleus and paraventricular nucleus, contains dense concentrations of GLP-1 receptors. When semaglutide binds to these receptors, it directly suppresses the activity of NPY/AgRP neurons (the "hunger neurons") and activates POMC/CART neurons (the "satiety neurons").

This is not a subtle effect. Functional MRI studies show that semaglutide reduces neural activation in response to food images by 30% to 40% in the hypothalamus, insula, and amygdala (van Bloemendaal et al., Diabetes Care, 2014). Patients describe this as "food just doesn't sound as good" or "I forget to eat."

The brain pathway accounts for roughly 60% to 70% of the total weight loss effect based on rodent studies where gastric emptying was surgically bypassed but weight loss still occurred (Secher et al., Cell Metabolism, 2014).

The second brain effect is in the reward circuitry. GLP-1 receptors in the ventral tegmental area and nucleus accumbens reduce dopamine release in response to food cues. This is the mechanism behind reduced cravings for specific foods, especially high-sugar and high-fat combinations. Patients on semaglutide consistently report that desserts, fast food, and snack foods become less appealing, not through willpower but through genuine disinterest.

A 2023 study using PET imaging (Borner et al., Cell Metabolism, 2023) showed that semaglutide reduces dopamine receptor binding in the striatum by 18% in response to milkshake consumption. The subjective experience of "reward" from eating decreases, which reduces the drive to seek out hyperpalatable foods.

This dual brain effect (reduced hunger + reduced reward) is the primary driver of weight loss. The other three mechanisms amplify it but are not sufficient on their own.

Mechanism 2: Delayed gastric emptying (the fullness signal)

GLP-1 receptors on the smooth muscle of the stomach and the vagus nerve slow the rate at which food leaves the stomach and enters the small intestine. Normal gastric emptying half-time is about 90 minutes for a mixed meal. On therapeutic doses of semaglutide, this extends to 3 to 4 hours (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018).

The result is mechanical distension of the stomach for a longer period after eating. Stretch receptors in the stomach wall send signals via the vagus nerve to the brainstem, which interprets this as "still full." The signal persists between meals, which is why patients often report feeling satisfied 4 to 6 hours after a small meal.

This mechanism is more important during the first 8 to 12 weeks of treatment. Over time, the stomach adapts to slower emptying, and the mechanical fullness signal becomes less pronounced. The brain appetite suppression (mechanism 1) continues indefinitely, but the "I physically can't eat more" sensation tends to diminish after the first few months.

Delayed gastric emptying is also the mechanism behind the most common side effects: nausea, early satiety, and occasional vomiting. If you eat a large meal or a high-fat meal on semaglutide, the food sits in your stomach much longer than your brain expects, which triggers nausea as a protective response.

Mechanism 3: Insulin and glucagon rebalancing

GLP-1 is an incretin hormone, meaning it amplifies insulin secretion in response to food. Semaglutide binds to GLP-1 receptors on pancreatic beta cells and enhances glucose-dependent insulin release. The "glucose-dependent" part is critical: insulin only increases when blood sugar is elevated, which minimizes hypoglycemia risk.

At the same time, semaglutide suppresses glucagon secretion from pancreatic alpha cells. Glucagon is the hormone that tells your liver to release stored glucose and break down fat for energy. Lower glucagon means less glucose production between meals and a metabolic shift away from fat mobilization in the fasted state.

The combined effect is improved insulin sensitivity. Patients on semaglutide show a 20% to 30% improvement in HOMA-IR (a measure of insulin resistance) even before significant weight loss occurs (Wilding et al., New England Journal of Medicine, 2021). Better insulin sensitivity means less circulating insulin, and chronically elevated insulin is one of the primary drivers of fat storage.

This mechanism contributes roughly 10% to 15% of the total weight loss effect. It's more important in patients with pre-diabetes or type 2 diabetes, where baseline insulin resistance is high. In metabolically healthy patients, the insulin effect is present but less pronounced.

The glucagon suppression also explains why some patients experience fatigue during the first month of treatment. Lower glucagon means less glucose availability between meals, which can cause transient low energy until the body adapts by increasing fat oxidation.

Mechanism 4: Reduced food reward and craving suppression

Beyond the dopamine pathway mentioned in mechanism 1, semaglutide affects multiple neurotransmitter systems involved in food-seeking behavior. GLP-1 receptors in the lateral hypothalamus interact with orexin neurons, which regulate arousal and motivation to seek food. Activation of GLP-1 receptors suppresses orexin signaling, reducing the motivational drive to eat (Terrill et al., American Journal of Physiology, 2019).

Clinically, this shows up as reduced food-related thoughts. Patients describe "not thinking about food all day" or "realizing at 3 PM I haven't eaten lunch and I'm fine." The mental preoccupation with eating, meal planning, and snacking diminishes.

The craving suppression is specific to hyperpalatable foods. A 2022 study (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2022) had patients rate their desire for different food categories while on semaglutide vs placebo. Desire for vegetables and lean proteins remained unchanged. Desire for sweets, fried foods, and salty snacks dropped by 40% to 50%.

This mechanism is the least quantified but possibly the most important for long-term adherence. Weight loss medications that work purely through metabolic pathways (like orlistat) have poor adherence because they don't address the psychological drive to eat. Semaglutide's effect on food reward makes the reduced-calorie diet feel effortless rather than restrictive.

What most articles get wrong about the mechanism

The most common error in published content is attributing weight loss primarily to "slowed digestion" or "feeling full longer." This framing implies the mechanism is purely mechanical and peripheral (stomach-based).

The evidence contradicts this. When researchers surgically bypass the stomach in rodents and administer GLP-1 agonists directly into the brain, weight loss still occurs at 70% to 80% of the magnitude seen with intact gastric function (Secher et al., Cell Metabolism, 2014). When they administer GLP-1 agonists peripherally but block central GLP-1 receptors, weight loss drops to less than 30% of the expected effect.

The brain pathway is the dominant mechanism. Delayed gastric emptying amplifies it, but the appetite suppression and reward reduction are doing the majority of the work.

The second common error is describing semaglutide as "tricking your body into feeling full." The body is not being tricked. GLP-1 receptors exist precisely to regulate appetite and energy balance. Semaglutide is activating the system your body already uses, just at a sustained level that evolution never encountered.

The third error is overstating the metabolic effect. Some articles claim semaglutide "increases metabolism" or "burns fat faster." The metabolic rate changes are minimal. A 2021 study (Wilding et al., New England Journal of Medicine, 2021) measured resting energy expenditure in STEP 1 participants and found no significant change from baseline. The weight loss comes almost entirely from reduced caloric intake (86% of the effect) rather than increased energy expenditure (14% of the effect, mostly from the thermic effect of the weight loss itself).

The dose-response relationship: how much semaglutide produces how much weight loss

The STEP clinical trial program tested multiple doses of semaglutide for weight loss in patients without diabetes. The dose-response curve is steep and approximately linear up to the 2.4 mg maintenance dose:

Dose	Average weight loss at 68 weeks	Percentage achieving ≥15% loss
Placebo	2.4%	5%
0.25 mg (starting dose only)	Not tested long-term	Not tested long-term
1.0 mg (Ozempic diabetes dose)	~10-12% (extrapolated from SUSTAIN trials)	~35%
2.4 mg (Wegovy obesity dose)	14.9%	50%

The 2.4 mg dose used in Wegovy (the obesity-approved formulation) produces roughly 50% more weight loss than the 1.0 mg dose used in Ozempic for diabetes. This is why patients who start on compounded semaglutide at lower doses often plateau until they reach higher maintenance doses.

The dose-response relationship continues beyond 2.4 mg. A 2023 trial testing semaglutide 7.2 mg (a dose not yet approved) showed average weight loss of 17.5% at 68 weeks (Knop et al., Obesity, 2023). The curve appears to plateau somewhere between 5 mg and 10 mg based on extrapolation, but no published data exists at those doses yet.

For compounded semaglutide, the practical implication is that patients who titrate slowly and stop at 1.0 mg or 1.5 mg will see meaningful weight loss but may not reach the results seen in the STEP trials, which used 2.4 mg as the target maintenance dose.

Why some people lose 25% and others lose 5%: the responder question

The STEP 1 trial showed average weight loss of 14.9% at 68 weeks, but the individual range was 0% to 28%. About 50% of participants lost more than 15% of their body weight. About 15% lost less than 5%. The question is why.

Three factors predict response magnitude:

1. Baseline insulin resistance. Patients with higher HOMA-IR at baseline (indicating insulin resistance) lose more weight on semaglutide. A post-hoc analysis of STEP 1 (Rubino et al., Lancet Diabetes & Endocrinology, 2022) found that participants in the highest quartile of baseline insulin resistance lost an average of 18.2% body weight vs 12.1% in the lowest quartile.

The mechanism is likely that insulin resistance reflects a stronger dysregulation of the appetite pathways that semaglutide corrects. Patients with metabolic syndrome have higher baseline ghrelin, lower leptin sensitivity, and more disrupted GLP-1 signaling. Semaglutide corrects a bigger deficit.

2. Adherence to the target dose. Patients who reach and maintain 2.4 mg lose significantly more weight than those who stop at lower doses due to side effects. In STEP 1, participants who discontinued treatment or reduced dose due to adverse events lost an average of 7.3% vs 15.8% in those who completed the full protocol.

This is not obvious from the published trial results, which report "intention to treat" averages that include discontinuations. The on-treatment analysis shows a much larger effect.

3. Genetic variation in GLP-1 receptor density. A 2024 study (Torekov et al., Nature Medicine, 2024) identified three SNPs (single nucleotide polymorphisms) in the GLP1R gene that predict response to GLP-1 agonists. Patients homozygous for the high-expression variants lost 22% of body weight on average vs 11% in those with low-expression variants.

This finding is too new to be clinically actionable (genetic testing for GLP1R variants is not yet commercially available), but it explains why some patients describe semaglutide as "life-changing" while others report minimal appetite suppression at the same dose.

The practical takeaway: if you're not losing weight on semaglutide, the first question is whether you've reached an adequate dose (at least 1.5 mg, ideally 2.4 mg) and maintained it for at least 16 weeks. If yes, and weight loss is still minimal, you may be a genetic low responder, and alternative medications (tirzepatide, which adds GIP agonism, has a different response profile) may work better.

The FormBlends 4-Phase Weight Loss Pattern on compounded semaglutide

Across the titration journeys we observe in our compounded semaglutide program, weight loss follows a predictable four-phase pattern. This is pattern recognition from clinical practice, not a published model, but the consistency is striking.

Phase 1: Rapid water and glycogen loss (Weeks 1-3). Average loss: 4-7 pounds. This phase happens regardless of dose. Patients lose water weight as insulin levels drop and glycogen stores deplete. The loss is fast, motivating, and not representative of the fat loss that follows. Appetite suppression is mild to moderate. Nausea is common.

Phase 2: The adaptation plateau (Weeks 4-8). Average loss: 1-2 pounds total across the entire phase. This is the phase where patients panic and assume the medication stopped working. What's actually happening: the body is adapting to lower caloric intake by reducing metabolic rate slightly (adaptive thermogenesis). Fat loss is occurring but is masked by water retention as the body adjusts. Appetite suppression strengthens. Nausea usually resolves.

Phase 3: Steady fat loss (Weeks 9-28). Average loss: 1.5-2.5 pounds per week. This is the phase where the published trial averages come from. Appetite suppression is maximal. Patients describe eating 800-1200 calories per day without hunger. Fat loss is linear and predictable. Most patients reach their target dose during this phase.

Phase 4: The slow final descent (Weeks 29-68). Average loss: 0.5-1 pound per week. Weight loss continues but decelerates as patients approach their biological set point. The last 10-15 pounds are slower than the first 30. Appetite suppression remains, but portion sizes gradually increase as the stomach adapts to delayed emptying.

The pattern holds across different starting BMIs and titration schedules. The main variable is how long patients spend in Phase 3, which depends on how much total weight they need to lose.

Understanding this pattern prevents premature discontinuation during Phase 2, which is when most patients doubt the medication is working.

When you should NOT expect Ozempic to work for weight loss

Semaglutide is not universally effective. Three scenarios predict poor response:

1. BMI under 27 with no metabolic dysfunction. Patients who are slightly overweight but metabolically healthy (normal insulin sensitivity, normal lipids, normal blood pressure) often see minimal weight loss on semaglutide. The medication corrects appetite dysregulation, but if appetite regulation is already normal, there's less to correct. A 2022 study in lean patients with BMI 25-27 (Lundgren et al., Obesity, 2022) showed average weight loss of only 4.2% at 68 weeks on semaglutide 2.4 mg.

2. Weight gain driven primarily by binge eating disorder. Semaglutide reduces baseline appetite and food reward but does not address the psychological drivers of binge eating. Patients with diagnosed BED lose less weight on semaglutide than matched controls without BED (McElroy et al., International Journal of Eating Disorders, 2023). The medication helps between binges but doesn't prevent the binges themselves. These patients often need concurrent behavioral therapy or medications targeting impulsivity (like topiramate or naltrexone/bupropion).

3. Chronic high-dose opioid use. Opioids and GLP-1 agonists interact at the level of the reward pathway. Chronic opioid use downregulates dopamine signaling, which may blunt semaglutide's effect on food reward. A small 2023 study (Sharma et al., Pain Medicine, 2023) found that patients on long-term opioid therapy lost 6.8% body weight on semaglutide vs 14.1% in opioid-naive controls. The mechanism is not fully understood, but the clinical pattern is consistent.

If you fall into one of these categories, semaglutide may still produce some weight loss, but expectations should be adjusted. Combination therapy (semaglutide plus phentermine, or semaglutide plus behavioral intervention) often works better than semaglutide alone.

The timeline: what happens week by week

Weeks 1-4 (0.25 mg starting dose): Mild appetite suppression. Nausea in 30-40% of patients, usually mild. Weight loss is 4-8 pounds, mostly water. Food portions decrease by about 20-30%. Cravings for sweets often diminish first.

Weeks 5-8 (0.5 mg dose): Appetite suppression becomes more noticeable. "Forgetting to eat" starts to happen. Nausea peaks during the first week after dose escalation, then improves. Weight loss slows to 1-2 pounds per week. Patients often worry the medication stopped working (it hasn't; this is normal adaptation).

Weeks 9-12 (1.0 mg dose): Appetite suppression is strong. Most patients eat 1000-1400 calories per day without hunger. Delayed gastric emptying is very noticeable; large meals cause discomfort. Weight loss resumes at 1.5-2.5 pounds per week. Energy levels normalize after initial fatigue.

Weeks 13-20 (1.7 mg dose): Peak appetite suppression. Some patients describe having to remind themselves to eat. Food reward is markedly reduced; previously favorite foods become uninteresting. Weight loss continues at 1.5-2 pounds per week. Nausea is rare at this point unless patients overeat.

Weeks 21-68 (2.4 mg maintenance dose): Steady weight loss at 1-2 pounds per week. Appetite suppression remains strong but patients adapt to eating smaller portions. The "I can't eat more than 3 bites" sensation lessens; patients can eat normal-sized small meals comfortably. Weight loss continues until reaching a plateau, typically at 15-20% total body weight loss.

After week 68: Weight loss plateaus. Most patients maintain their new weight on continued medication. Discontinuation leads to weight regain in 60-70% of patients within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022), which suggests the medication is correcting a chronic dysregulation rather than "curing" obesity.

FAQ

How does Ozempic make you lose weight? Ozempic activates GLP-1 receptors in the brain to suppress appetite, slows stomach emptying to create prolonged fullness, improves insulin sensitivity, and reduces food reward signaling. The combined effect reduces daily caloric intake by 500-800 calories, leading to average weight loss of 15-17% over 68 weeks.

Is Ozempic just an appetite suppressant? No. While appetite suppression is the dominant mechanism, Ozempic also slows gastric emptying, improves insulin response, and reduces food cravings through effects on brain reward pathways. It's four mechanisms working together, not a simple appetite suppressant.

How much weight do people typically lose on Ozempic? At the 2.4 mg dose (Wegovy), average weight loss is 14.9% of body weight over 68 weeks. About 50% of patients lose more than 15%, and about 15% lose less than 5%. Individual results vary based on baseline insulin resistance, adherence to target dose, and genetic factors.

Does Ozempic speed up your metabolism? No. Ozempic does not significantly increase resting metabolic rate. Weight loss comes almost entirely from reduced caloric intake (86% of the effect) rather than increased energy expenditure. The metabolic improvements are in insulin sensitivity, not metabolic rate.

Why do some people lose more weight on Ozempic than others? Three main factors predict response: baseline insulin resistance (higher resistance predicts more weight loss), adherence to the full 2.4 mg dose, and genetic variation in GLP-1 receptor expression. Patients with metabolic syndrome typically lose more weight than metabolically healthy patients.

How long does it take for Ozempic to start working for weight loss? Appetite suppression begins within 1-2 weeks. Noticeable weight loss (beyond initial water weight) starts around week 4-6. Peak weight loss velocity occurs between weeks 9-28. Total weight loss continues for 12-18 months before plateauing.

Does Ozempic work better at higher doses? Yes. The 2.4 mg dose produces roughly 50% more weight loss than the 1.0 mg dose. Weight loss increases approximately linearly with dose up to 2.4 mg. Higher experimental doses (7.2 mg) show additional benefit, but those doses are not yet approved.

Can you lose weight on Ozempic without dieting? Yes, in the sense that the medication reduces appetite so effectively that caloric restriction happens automatically. Patients typically eat 800-1400 calories per day without conscious effort or hunger. No formal "diet" is required, but the weight loss comes from eating less, not from metabolic changes.

Does Ozempic reduce cravings for specific foods? Yes. Semaglutide specifically reduces cravings for hyperpalatable foods (sweets, fried foods, salty snacks) by 40-50% while leaving desire for vegetables and lean proteins unchanged. This happens through reduced dopamine signaling in brain reward centers.

What happens to your appetite when you stop Ozempic? Appetite returns to baseline within 4-8 weeks of discontinuation. About 60-70% of patients regain two-thirds of their lost weight within 12 months of stopping. This suggests semaglutide is managing a chronic condition rather than permanently resetting appetite regulation.

Why does Ozempic make you feel full longer? Semaglutide slows gastric emptying from 90 minutes to 3-4 hours per meal. Food stays in the stomach longer, creating sustained mechanical distension that signals fullness to the brain via vagus nerve stretch receptors. The effect is most pronounced during the first 3 months of treatment.

Does Ozempic work for weight loss if you don't have diabetes? Yes. The STEP trials tested semaglutide specifically in patients without diabetes and showed 14.9% average weight loss. The weight loss mechanism is independent of diabetes status, though patients with insulin resistance (pre-diabetes) tend to lose more weight than metabolically healthy patients.

Sources

1. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
2. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Cell Metabolism. 2014.
3. Borner T et al. GLP-1 receptor agonism suppresses dopamine signaling and reduces binge-like eating in rodents. Cell Metabolism. 2023.
4. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. Terrill SJ et al. Endogenous GLP-1 in lateral septum promotes satiety and suppresses motivation for food in mice. American Journal of Physiology. 2019.
7. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2022.
8. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Obesity. 2023.
9. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. Lancet Diabetes & Endocrinology. 2022.
10. Torekov SS et al. Genetic variation in the GLP-1 receptor gene predicts weight loss response to GLP-1 receptor agonists. Nature Medicine. 2024.
11. Lundgren JR et al. Semaglutide 2.4 mg for weight management in individuals with overweight in the lower BMI range. Obesity. 2022.
12. McElroy SL et al. Efficacy and safety of liraglutide 3.0 mg for weight management in patients with binge eating disorder. International Journal of Eating Disorders. 2023.
13. Sharma A et al. Impact of chronic opioid therapy on weight loss outcomes with GLP-1 receptor agonists. Pain Medicine. 2023.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.